CURE’s neuroendocrine cancer page features the latest cancer news and updates on neuroendocrine cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in neuroendocrine cancer.
February 2nd 2025
Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.
November 30th 2024